# Mariano Provencio

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mariano-provencio/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,329 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 71 |
| i10-index | 308 |
| Last Known Institution | Hospital Universitario Puerta de Hierro Majadahonda |
| OpenAlex ID | https://openalex.org/A5085499011 |
| ORCID iD | https://orcid.org/0000-0001-6315-7919 |
| Works | 976 |

## Researcher papers

- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Perioperative Nivolumab in Resectable Lung Cancer](https://scholariq.org/papers/perioperative-nivolumab-in-resectable-lung-cancer/)
- [IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy](https://scholariq.org/papers/iaslc-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer/)
- [First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-advanced-nsclc-4-year-outcomes-from-the/)
- [Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-chemotherapy-as-first-line-treatment-in/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Hospital Universitario Puerta de Hierro Majadahonda](https://scholariq.org/institutions/hospital-universitario-puerta-de-hierro-majadahonda/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.